SRPT

Sarepta looks optically cheap — a $1.79B market cap against $1.86B of FY2025 revenue is a 1.0x P/S — but the price reflects genuine existential risk, not a bargain. The defining event in the filing is the November 3, 2025 ESSENCE readout: the confirmatory trial meant to verify the clinical benefit of AMONDYS 45 and VYONDYS 53 'did not show statistical significance on the study's primary endpoint,' and management can only say it 'intends to discuss with FDA the potential pathway forward.' Because these are FDA post-marketing requirements tied to accelerated-approval products that already generate revenue, a meaningful slice of the top line now sits under regulatory threat with no quantifiable outcome — the textbook definition of unknowable risk.

The numbers corroborate a business that has rolled over. After compounding from $612M (FY2021) to $1.79B (FY2024), revenue growth collapsed to +4.3% in FY2025, and the company swung from a $235M profit in FY2024 to a $713M net loss — a roughly $948M deterioration that drove operating margin to -37.5%, ROE to -62.5%, and an accumulated deficit to -$4.88B. This is not a clean R&D-investment loss either: operating cash flow was -$205M, so the franchise is burning cash even before the ESSENCE overhang.